Mangoceuticals shares surge 111.30% intraday after board approves re-pricing of CEO's stock options to $0.45 covering 2.13M shares to enhance management incentives.

Mangoceuticals surged 111.30% intraday trading, with the company announcing that its board approved the repricing of stock options held by CEO Jacob Cohen to $0.45 per share, covering 2,133,333 shares in total, to enhance management incentives. The company operates through a telemedicine platform in the U.S., developing, marketing, and selling male health products, including brands for erectile dysfunction, hair loss, hormone balance, and weight loss.